Insertion/Deletion Polymorphisms in the Promoter Are a Risk Factor for Bladder Exstrophy Epispadias Complex

English version České info

Bladder exstrophy epispadias complex (BEEC) is a severe congenital anomaly; however, the genetic and molecular mechanisms underlying the formation of BEEC remain unclear. TP63, a member of TP53 tumor suppressor gene family, is expressed in bladder urothelium and skin over the external genitalia during mammalian development. It plays a role in bladder development. We have previously shown that p63^−/− mouse embryos developed a bladder exstrophy phenotype identical to human BEEC. We hypothesised that TP63 is involved in human BEEC pathogenesis. RNA was extracted from BEEC foreskin specimens and, as in mice, ΔNp63 was the predominant p63 isoform. ΔNp63 expression in the foreskin and bladder epithelium of BEEC patients was reduced. DNA was sequenced from 163 BEEC patients and 285 ethnicity-matched controls. No exon mutations were detected. Sequencing of the ΔNp63 promoter showed 7 single nucleotide polymorphisms and 4 insertion/deletion (indel) polymorphisms. Indel polymorphisms were associated with an increased risk of BEEC. Significantly the sites of indel polymorphisms differed between Caucasian and non-Caucasian populations. A 12-base-pair deletion was associated with an increased risk with only Caucasian patients (p = 0.0052 Odds Ratio (OR) = 18.33), whereas a 4-base-pair insertion was only associated with non-Caucasian patients (p = 0.0259 OR = 4.583). We found a consistent and statistically significant reduction in transcriptional efficiencies of the promoter sequences containing indel polymorphisms in luciferase assays. These findings suggest that indel polymorphisms of the ΔNp63 promoter lead to a reduction in p63 expression, which could lead to BEEC.

Vyšlo v časopise: Insertion/Deletion Polymorphisms in the Promoter Are a Risk Factor for Bladder Exstrophy Epispadias Complex. PLoS Genet 8(12): e32767. doi:10.1371/journal.pgen.1003070
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003070

Souhrn

Zdroje

1. Martinez-FriasML, BermejoE, Rodriguez-PinillaE, FriasJL (2001) Exstrophy of the cloaca and exstrophy of the bladder: two different expressions of a primary developmental field defect. Am J Med Genet 99 : 261–269.

2. GearhartJP, JeffsRD (1989) State-of-the-art reconstructive surgery for bladder exstrophy at the Johns Hopkins Hospital. Am J Dis Child 143 : 1475–1478.

3. BoyadjievSA, DodsonJL, RadfordCL, AshrafiGH, BeatyTH, et al. (2004) Clinical and molecular characterization of the bladder exstrophy-epispadias complex: analysis of 232 families. BJU Int 94 : 1337–1343.

4. NelsonCP, DunnRL, WeiJT (2005) Contemporary epidemiology of bladder exstrophy in the United States. J Urol 173 : 1728–1731.

5. FrosterUG, HeinritzW, BennekJ, HornLC, FaberR (2004) Another case of autosomal dominant exstrophy of the bladder. Prenat Diagn 24 : 375–377.

6. LudwigM, RuschendorfF, SaarK, HubnerN, SiekmannL, et al. (2009) Genome-wide linkage scan for bladder exstrophy-epispadias complex. Birth Defects Res A Clin Mol Teratol 85 : 174–178.

7. ShapiroE, LeporH, JeffsRD (1984) The inheritance of the exstrophy-epispadias complex. J Urol 132 : 308–310.

8. ReutterH, QiL, GearhartJP, BoemersT, EbertAK, et al. (2007) Concordance analyses of twins with bladder exstrophy-epispadias complex suggest genetic etiology. Am J Med Genet A 143A: 2751–2756.

9. ChengW, JacobsWB, ZhangJJ, MoroA, ParkJH, et al. (2006) DeltaNp63 plays an anti-apoptotic role in ventral bladder development. Development 133 : 4783–4792.

10. KosterMI, KimS, MillsAA, DeMayoFJ, RoopDR (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18 : 126–131.

11. YangA, KaghadM, WangY, GillettE, FlemingMD, et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2 : 305–316.

12. MillsAA, ZhengB, WangXJ, VogelH, RoopDR, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398 : 708–713.

13. BaskinLS, HaywardSW, YoungP, CunhaGR (1996) Role of mesenchymal-epithelial interactions in normal bladder development. J Urol 156 : 1820–1827.

14. ChingBJ, WittlerL, ProskeJ, YagnikG, QiL, et al. (2010) p63 (TP73L) a key player in embryonic urogenital development with significant dysregulation in human bladder exstrophy tissue. Int J Mol Med 26 : 861–867.

15. RodriguezS, GauntTR, DayIN (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169 : 505–514.

16. GauntTR, RodriguezS, DayIN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’. BMC Bioinformatics 8 : 428.

17. NiC, YeY, WangM, QianH, SongZ, et al. (2009) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with risk of coal workers' pneumoconiosis. J Toxicol Environ Health A 72 : 712–716.

18. Miceli-RichardC, GestermannN, IttahM, CometsE, LoiseauP, et al. (2009) The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome. Arthritis Rheum 60 : 1991–1997.

19. BurchardEG, SilvermanEK, RosenwasserLJ, BorishL, YandavaC, et al. (1999) Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med 160 : 919–922.

20. KulozikAE, Bellan-KochA, BailS, KohneE, KleihauerE (1991) Thalassemia intermedia: moderate reduction of beta globin gene transcriptional activity by a novel mutation of the proximal CACCC promoter element. Blood 77 : 2054–2058.

21. SunT, GaoY, TanW, MaS, ShiY, et al. (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39 : 605–613.

22. FrankB, RigasSH, BermejoJL, WiestlerM, WagnerK, et al. (2008) The CASP8 −652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 111 : 139–144.

23. HaimanCA, GarciaRR, KolonelLN, HendersonBE, WuAH, et al. (2008) A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 40 : 259–260; author reply 260–251.

24. PittmanAM, BroderickP, SullivanK, FieldingS, WebbE, et al. (2008) CASP8 variants D302H and −652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer 98 : 1434–1436.

25. IhrieRA, MarquesMR, NguyenBT, HornerJS, PapazogluC, et al. (2005) Perp is a p63-regulated gene essential for epithelial integrity. Cell 120 : 843–856.

26. QiL, ChenK, HurDJ, YagnikG, LakshmananY, et al. (2011) Genome-wide expression profiling of urinary bladder implicates desmosomal and cytoskeletal dysregulation in the bladder exstrophy-epispadias complex. Int J Mol Med 27 : 755–765.

27. CelliJ, DuijfP, HamelBC, BamshadM, KramerB, et al. (1999) Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99 : 143–153.

28. MaasSM, de JongTP, BussP, HennekamRC (1996) EEC syndrome and genitourinary anomalies: an update. Am J Med Genet 63 : 472–478.

29. ChuangsuwanichT, SunsaneevithayakulP, MuangsomboonK, LimwongseC (2005) Ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome presenting with a large nephrogenic cyst, severe oligohydramnios and hydrops fetalis: a case report and review of the literature. Prenat Diagn 25 : 210–215.

30. ChilosiM, ZamoA, BrighentiA, MalpeliG, MontagnaL, et al. (2003) Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 443 : 175–183.

31. PfafflMW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.

32. InceTA, CvikoAP, QuadeBJ, YangA, McKeonFD, et al. (2002) p63 Coordinates anogenital modeling and epithelial cell differentiation in the developing female urogenital tract. Am J Pathol 161 : 1111–1117.

33. YangA, SchweitzerR, SunD, KaghadM, WalkerN, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398 : 714–718.